BioStock | SynAct Pharma Q2 report comment | August 2022
BioStock interviews SynAct Pharma’s CEO Jeppe Øvlesen and CFO Patrik Renblad about the second quarter of 2022.
0:00 Welcome
0:18 Summary of important events in Q2
1:20 Financial numbers in the interim report
3:45 How long will the current cash position fund the clinical development?
4:28 Listing on Nasdaq Stockholm Main Market
5:26 Benefits and requirements following uplisting
9:00 Updated study design in kidney diseases
10:05 Main focus during second half of 2022
Read BioStock's latest article about SynAct Pharma
https://www.biostock.se/2022/07/synac...
Subscribe and follow BioStock on: YouTube https://bit.ly/Biostock
LinkedIn: / biostock
Facebook: / biostock.se
Twitter: / biostock_swe https://www.biostock.se/
#biostock #lifescience #SynActPharma
About BioStock BioStock is Scandinavia's leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office is found at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies, while our second editorial office is located in central Stockholm with proximity to both life science companies and financial players. We have TV studios on both sites.